-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Benzinga·08/06/2026 14:09:35
Listen to the news
Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.